@article{MTMT:34565525,
	title = {Hypermucinosus és kehelysejtszegény, gyulladásos bélbetegséghez társult, non-conventionalis dysplasia colorectalis adenocarcinoma mellett [Hypermucinous and goblet cell-deficient, IBD-associated, non-conventional dysplasia besides colorectal adenocarcinoma]. [esetismertetés]},
	url = {https://m2.mtmt.hu/api/publication/34565525},
	author = {Almási, Szintia and Baráth, Bence and Szaszák, Panna and Kővári, Bence and Sejben, Anita},
	doi = {10.1556/650.2023.32946},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {164},
	unique-id = {34565525},
	issn = {0030-6002},
	abstract = {A gyulladásos bélbetegséggel (IBD) élő betegekben a colorectalis carcinoma kialakulásának esélye az átlagpopulációban észleltek kétszerese. Az invazív daganatokat megelőzően ezekben a betegekben nagyobb a rizikó dysplasia kialakulására is. Az utóbbi években számos, IBD-hez társult, ún. non-conventionalis dysplasia altípust azonosítottak, melyekről a jelenleg is zajló kutatásoknak köszönhetően egyre több információval rendelkezünk. Egy 62 éves, 14 éve relabáló colitis ulcerosával diagnosztizált és kezelt nőbeteg subtotalis colectomiás preparátumában colitis ulcerosa mellett a sigmabélben invazív adenocarcinomát azonosítottunk mucinosus területekkel. A daganat közvetlen környezetében kehelysejtszegény, valamint hypermucinosus IBD-hez társult, non-conventionalis dysplasiát észleltünk, az utóbbinak intestinalis és foveolaris altípusa is elkülöníthető volt. A felhalmozódó ismeretek tükrében az IBD-hez társult, non-conventionalis dysplasiák ismerete több szempontból is fontos lehet a diagnosztikában és a klinikai ellátásban, ugyanis ezek a laesiók makroszkóposan laposak vagy láthatatlanok lehetnek, megnehezítve a dysplasia endoszkópos szűrését. Ismeretük a patológus számára kiemelten fontos, hiszen a reaktív és reparatív folyamatoktól való elkülönítésük sokszor nagy kihívást jelent. Továbbá, a hagyományos típusoknál gyakrabban társultak ’high-grade’ dysplasiával, valamint colorectalis carcinomával. Molekuláris hátterüket tekintve, sokkal gyakrabban észlelhető bennük aneuploidia. Mindezen ismeretek a hagyományos neoplasiákhoz képest rosszabb prognózis rizikót vetítenek elő, és az esetlegesen nehezen azonosítható endoszkópos képüket is figyelembe véve felismerésük után az IBD-s betegek szorosabb utánkövetése és esetleges véletlenszerű biopsziás mintavétel mérlegelendő. Orv Hetil. 2023; 164(51): 2039–2044.},
	year = {2023},
	eissn = {1788-6120},
	pages = {2039-2044},
	orcid-numbers = {Baráth, Bence/0000-0001-5713-8471; Kővári, Bence/0000-0002-4498-8781; Sejben, Anita/0000-0002-9434-2989}
}

@article{MTMT:33941648,
	title = {Neuregulin-1β Improves Uremic Cardiomyopathy and Renal Dysfunction in Rats},
	url = {https://m2.mtmt.hu/api/publication/33941648},
	author = {Sárközy, Márta and Watzinger, Simon and Kovács, Zsuzsanna and Acar, Eylem and Márványkövi, Fanni and Szűcs, Gergő and Lauber, Gülsüm Yilmaz and Galla, Zsolt and Siska, Andrea and Földesi, Imre and Fintha, Attila and Kriston, András and Kovács, Ferenc and Horváth, Péter and Kővári, Bence and Cserni, Gábor and Krenács, Tibor and Szabó, Petra Lujza and Szabó, Gábor Tamás and Monostori, Péter and Zins, Karin and Abraham, Dietmar and Csont, Tamás Bálint and Pokreisz, Peter and Podesser, Bruno K. and Kiss, Attila},
	doi = {10.1016/j.jacbts.2023.03.003},
	journal-iso = {JACC-BASIC TRANSL SC},
	journal = {JACC:BASIC TO TRANSLATIONAL SCIENCE},
	volume = {8},
	unique-id = {33941648},
	issn = {2452-302X},
	year = {2023},
	eissn = {2452-302X},
	pages = {1160-1176},
	orcid-numbers = {Sárközy, Márta/0000-0002-5929-2146; Kovács, Zsuzsanna/0000-0002-4197-4579; Márványkövi, Fanni/0000-0002-5114-1319; Szűcs, Gergő/0000-0003-1874-2718; Galla, Zsolt/0000-0002-9166-1212; Földesi, Imre/0000-0002-3329-8136; Fintha, Attila/0000-0002-0519-8170; Kővári, Bence/0000-0002-4498-8781; Cserni, Gábor/0000-0003-1344-7744; Krenács, Tibor/0000-0001-9164-065X; Monostori, Péter/0000-0003-3591-6054; Csont, Tamás Bálint/0000-0001-5792-2768; Pokreisz, Peter/0000-0003-2810-9000}
}

@article{MTMT:33814839,
	title = {Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort},
	url = {https://m2.mtmt.hu/api/publication/33814839},
	author = {Pipek, Orsolya Anna and Alpár, Donát and Rusz, Orsolya and Bödör, Csaba and Udvarnoki, Zoltán András and Medgyes-Horváth, Anna and Csabai, István and Szállási, Zoltán and Madaras, Lilla and Kahán, Zsuzsanna and Cserni, Gábor and Kővári, Bence and Kulka, Janina and Tőkés, Anna-Mária},
	doi = {10.3390/ijms24108553},
	journal-iso = {INT J MOL SCI},
	journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
	volume = {24},
	unique-id = {33814839},
	issn = {1661-6596},
	abstract = {A limited number of studies have focused on the mutational landscape of breast cancer in different ethnic populations within Europe and compared the data with other ethnic groups and databases. We performed whole-genome sequencing of 63 samples from 29 Hungarian breast cancer patients. We validated a subset of the identified variants at the DNA level using the Illumina TruSight Oncology (TSO) 500 assay. Canonical breast-cancer-associated genes with pathogenic germline mutations were CHEK2 and ATM. Nearly all the observed germline mutations were as frequent in the Hungarian breast cancer cohort as in independent European populations. The majority of the detected somatic short variants were single-nucleotide polymorphisms (SNPs), and only 8% and 6% of them were deletions or insertions, respectively. The genes most frequently affected by somatic mutations were KMT2C (31%), MUC4 (34%), PIK3CA (18%), and TP53 (34%). Copy number alterations were most common in the NBN, RAD51C, BRIP1, and CDH1 genes. For many samples, the somatic mutational landscape was dominated by mutational processes associated with homologous recombination deficiency (HRD). Our study, as the first breast tumor/normal sequencing study in Hungary, revealed several aspects of the significantly mutated genes and mutational signatures, and some of the copy number variations and somatic fusion events. Multiple signs of HRD were detected, highlighting the value of the comprehensive genomic characterization of breast cancer patient populations.},
	year = {2023},
	eissn = {1422-0067},
	orcid-numbers = {Pipek, Orsolya Anna/0000-0001-8109-0340; Rusz, Orsolya/0000-0001-5726-4072; Bödör, Csaba/0000-0002-0729-692X; Udvarnoki, Zoltán András/0000-0001-7086-235X; Medgyes-Horváth, Anna/0000-0003-4435-5797; Csabai, István/0000-0001-9232-9898; Szállási, Zoltán/0000-0001-5395-7509; Madaras, Lilla/0000-0002-4137-4696; Kahán, Zsuzsanna/0000-0002-5021-8775; Cserni, Gábor/0000-0003-1344-7744; Kővári, Bence/0000-0002-4498-8781; Kulka, Janina/0000-0001-6498-5943; Tőkés, Anna-Mária/0000-0002-9581-7536}
}

@article{MTMT:33539208,
	title = {Inflammatory Bowel Disease-Mimicking Colitis Associated With Nintedanib-Based Therapy in a Lung Cancer Patient},
	url = {https://m2.mtmt.hu/api/publication/33539208},
	author = {Sejben, Anita and Sejben, István and Annamária, Budai and Gregory, Y. Lauwers and Kővári, Bence},
	doi = {10.1177/10668969221143472},
	journal-iso = {INT J SURG PATHOL},
	journal = {INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY},
	volume = {31},
	unique-id = {33539208},
	issn = {1066-8969},
	year = {2023},
	eissn = {1940-2465},
	pages = {1326-1328},
	orcid-numbers = {Sejben, Anita/0000-0002-9434-2989; Kővári, Bence/0000-0002-4498-8781}
}

@article{MTMT:33202311,
	title = {Interobserver agreement of estimating the extent of intestinal metaplasia in patients with chronic atrophic gastritis},
	url = {https://m2.mtmt.hu/api/publication/33202311},
	author = {Lerch, Julia M and Pai, Rish K and Brown, Ian and Gill, Anthony J and Jain, Dhanpat and Kővári, Bence and Kushima, Ryoji and Sheahan, Kieran and Slavik, Tomas and Srivastava, Amitabh and Lauwers, Gregory Y and Langner, Cord},
	doi = {10.1007/s00428-021-03245-9},
	journal-iso = {VIRCHOWS ARCH},
	journal = {VIRCHOWS ARCHIV},
	volume = {480},
	unique-id = {33202311},
	issn = {0945-6317},
	abstract = {The extent of gastric intestinal metaplasia (GIM) can be used to determine the risk of gastric cancer. Eleven international gastrointestinal expert pathologists estimated the extent of GIM on haematoxylin and eosin (H&E)- and Alcian blue-Periodic acid Schiff (AB-PAS)-stained slides of 46 antrum biopsies in 5% increments. Interobserver agreement was tested with the intraclass correlation coefficient (ICC). Correlation between standard deviation and extent of GIM was evaluated with the Spearman correlation. The interobserver agreement was very good (ICC = 0.983, 95% confidence interval (CI) 0.975-0.990). The use of AB-PAS did not increase the agreement (ICC = 0.975, 95% CI 0.961-0.985). Cases with a higher amount of metaplastic epithelium demonstrated a higher standard deviation (rs = 0.644; p < 0.01), suggesting lower diagnostic accuracy in cases with extensive GIM. In conclusion, estimating the extent of GIM on H&E-stained slides in patients with chronic atrophic gastritis can be achieved satisfactorily with high interobserver agreement, at least among international expert gastrointestinal pathologists.},
	keywords = {INTEROBSERVER AGREEMENT; Chronic atrophic gastritis; Intestinal Metaplasia; Gastric precancerous lesion},
	year = {2022},
	eissn = {1432-2307},
	pages = {1277-1281},
	orcid-numbers = {Kővári, Bence/0000-0002-4498-8781}
}

@article{MTMT:33202308,
	title = {Metachronous double-hit by transarterial chemoembolisation (TACE) with fotemustine inducing dysplasia-like atypia in the gallbladder and stomach-A diagnostic pitfall},
	url = {https://m2.mtmt.hu/api/publication/33202308},
	author = {Varelas, Ana I and Kővári, Bence and Bruckner, Elisabeth and Lauwers, Gregory Y and Langner, Cord},
	doi = {10.1111/his.14653},
	journal-iso = {HISTOPATHOLOGY},
	journal = {HISTOPATHOLOGY},
	volume = {81},
	unique-id = {33202308},
	issn = {0309-0167},
	keywords = {immunohistochemistry; Histology; gastroduodenal ulcer; Drug-induced injury; gangrenous cholecystitis},
	year = {2022},
	eissn = {1365-2559},
	pages = {128-130},
	orcid-numbers = {Kővári, Bence/0000-0002-4498-8781}
}

@article{MTMT:33202305,
	title = {Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer},
	url = {https://m2.mtmt.hu/api/publication/33202305},
	author = {Kim, Dae Won and Kim, Young-Chul and Kővári, Bence and Chung, Vincent and Alese, Olatunji B and El-Rayes, Bassel F and Li, Daneng and Park, Wungki and Kim, Richard D},
	doi = {10.1016/j.ejca.2022.09.014},
	journal-iso = {Eur J Cancer},
	journal = {European journal of cancer (Oxford, England : 1990)},
	volume = {176},
	unique-id = {33202305},
	abstract = {Our previous phase II study demonstrated that nivolumab provides modest but durable clinical efficacy in patients with refractory biliary tract cancer, suggesting the significant clinical benefit of nivolumab in selected patients and the necessity of predictive biomarkers. We evaluated clinicopathological characteristics and tumour microenvironment of the patients who were enrolled the trial to identify potential biomarkers.Baseline clinicopathological characteristics and pretreatment tumour samples were collected. The obtained tumour samples were assessed for whole exome sequencing, RNA sequencing and immunohistochemistry. Their correlations with clinical outcome were analysed.Pretreatment tumour evaluation revealed PD-L1 expression on tumour, CD8 T cell infiltration and high ratio of CD8 T cell/regulatory T cell in tumour microenvironment were significantly associated with prolonged progression-free survival (PFS), while PD-1 expression on lymphocytes and CD68 macrophages infiltration in tumour microenvironment had no predictive role. Asian patients (N = 3) had improved PFS and disease control rate compared with non-Asian (N = 54). A six-gene predictive model was constructed by evaluation of total 23,550 candidate genes from RNA sequencing of baseline tumour samples using LASSO-Cox regression analysis, and high score of the six-gene prediction model was associated with prolonged PFS.This study suggests that PD-L1 expression on tumour, CD8 T cell infiltration and high ratio of CD8/regulatory T cells and six-gene expression profile in tumour microenvironment may be potential predictive biomarkers of nivolumab in biliary tract cancers. Further studies are needed to confirm these findings.},
	keywords = {biomarker; nivolumab; Biliary tract cancer},
	year = {2022},
	eissn = {1879-0852},
	pages = {171-180},
	orcid-numbers = {Kővári, Bence/0000-0002-4498-8781}
}

@article{MTMT:32955612,
	title = {A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer},
	url = {https://m2.mtmt.hu/api/publication/32955612},
	author = {Kim, Richard D. and Kővári, Bence and Martinez, Maria and Xie, Hao and Sahin, Ibrahim H. and Mehta, Rutika and Strosberg, Jonathan and Imanirad, Iman and Ghayouri, Masoumeh and Kim, Young-chul and Kim, Dae Won},
	doi = {10.1016/j.ejca.2022.03.026},
	journal-iso = {EUR J CANCER},
	journal = {EUROPEAN JOURNAL OF CANCER},
	volume = {169},
	unique-id = {32955612},
	issn = {0959-8049},
	abstract = {Aim: In contrast to mismatch repair deficient (dMMR) colorectal cancer (CRC), mismatch repair proficient (pMMR) CRC is usually unresponsive to anti-PD-1 immunotherapy. Recent preclinical data suggest that regorafenib may enhance the antitumor activity of anti-PD-1 immunotherapy. However, the safety and efficacy of regorafenib plus nivolumab have not been established in patients with refractory metastatic pMMR CRC. This study aimed to evaluate the safety and efficacy of regorafenib plus nivolumab in metastatic pMMRMethod: This was a phase I/Ib study with standard 3 + 3 design plus dose expansion of the maximum tolerated dose (MTD) in patients with refractory metastatic pMMR CRC. Patients were treated with regorafenib combined with nivolumab. The primary end-points were doselimiting toxicity (DLT) and MTD. The secondary end-points were objective response rate, safety and overall survival (OS).Results: A total of 52 patients were enrolled, and 51 patients received at least one dose of treatment. Three patients experienced DLT (all grade 3 rash). MTD was regorafenib 80 mg and nivolumab 240 mg every 2 weeks. Most common grade 3/4 treatment-related adverse events were hypertension (16%), rash (10%) and anaemia (6%). Among 40 evaluable patients, stable disease, and disease control rate was 63%. The median progression-free survival and OS were 4.3 and 11.1 months, respectively.Conclusions: Regorafenib plus nivolumab appears to be well tolerated with limited anticancer activity in metastatic pMMR CRC. Trial Registration: ClinicalTrials.gov identifier: NCT03712943. 2022 Elsevier Ltd. All rights reserved.},
	keywords = {colorectal cancer; biomarker; nivolumab; regorafenib; Phase I study; metastatic CRC},
	year = {2022},
	eissn = {1879-2995},
	pages = {93-102},
	orcid-numbers = {Kővári, Bence/0000-0002-4498-8781; Strosberg, Jonathan/0000-0001-8405-218X}
}

@article{MTMT:32710978,
	title = {Subtyping intestinal metaplasia in patients with chronic atrophic gastritis: an interobserver variability study},
	url = {https://m2.mtmt.hu/api/publication/32710978},
	author = {Lerch, Julia M. and Pai, Rish K. and Brown, Ian and Gill, Anthony J. and Jain, Dhanpat and Kővári, Bence and Kushima, Ryoji and Sheahan, Kieran and Slavik, Tomas and Srivastava, Amitabh and Lauwers, Gregory Y. and Langner, Cord},
	doi = {10.1016/j.pathol.2021.12.288},
	journal-iso = {PATHOLOGY},
	journal = {PATHOLOGY},
	volume = {54},
	unique-id = {32710978},
	issn = {0031-3025},
	year = {2022},
	eissn = {1465-3931},
	pages = {262-268},
	orcid-numbers = {Pai, Rish K./0000-0002-2692-221X; Kővári, Bence/0000-0002-4498-8781; Langner, Cord/0000-0002-0322-8460}
}

@article{MTMT:32637299,
	title = {Exercise training worsens cardiac performance in males but does not change ejection fraction and improves hypertrophy in females in a mouse model of metabolic syndrome},
	url = {https://m2.mtmt.hu/api/publication/32637299},
	author = {Tóth, Erzsébet Melinda and Sárközy, Márta and Szűcs, Gergő and Dukay, Brigitta and Hajdu, Petra and Zvara, Ágnes and Puskás, László and Szebeni, Gábor and Ruppert, Zsófia and Csonka, Csaba and Kovács, Ferenc and Kriston, András and Horváth, Péter and Kővári, Bence and Cserni, Gábor and Csont, Tamás Bálint and Sántha, Miklós},
	doi = {10.1186/s13293-022-00414-6},
	journal-iso = {BIOL SEX DIFFER},
	journal = {BIOLOGY OF SEX DIFFERENCES},
	volume = {13},
	unique-id = {32637299},
	year = {2022},
	eissn = {2042-6410},
	orcid-numbers = {Sárközy, Márta/0000-0002-5929-2146; Szűcs, Gergő/0000-0003-1874-2718; Szebeni, Gábor/0000-0002-6998-5632; Csonka, Csaba/0000-0003-2532-6261; Kővári, Bence/0000-0002-4498-8781; Cserni, Gábor/0000-0003-1344-7744; Csont, Tamás Bálint/0000-0001-5792-2768}
}